<DOC>
	<DOCNO>NCT01736189</DOCNO>
	<brief_summary>In usual clinical setting , patient Rheumatoid Arthritis receive adalimumab ( Humira® ) high-dose Methotrexate ( ≥12 mg/week ) investigate prospectively effectiveness accord Disease Activity Score 28 , modify Total Sharp Score , measure , well safety term incidence pattern occurrence adverse drug reaction .</brief_summary>
	<brief_title>Special Investigation Patients With Rheumatoid Arthritis ( Combo Study ; Adalimumab With High Dose Methotrexate )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>The subject study RA patient adalimumab administer . They satisfy follow condition : Disease duration RA ≤2 year MTX administration ≥3 month Dose MTX ≥12mg/week DAS28CRP &gt; 3.2 Patients previously treat biologics ( include TNF inhibitor others )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>